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The underlining principle of IR spectroscopy is that the molecular 
structure can be revealed by exciting the vibrational modes in materials. The 
absorption bands in an IR spectrum are thus a fingerprint of the molecular 
composition. Within the linear range of Lambert-Beer law, the absorbance is 
a quantitative measure of the molecular species concentration.
Modern IR spectrometers are based on Fourier Transform (FT) 
interferometer and they are commonly coupled to all-reflective IR 
microscopes enabling the acquisition of spatially resolved IR information, 
for instance, in an individual cell 1. When the microscope aperture defining 
the IR imaging spot at the sample is reduced to 20 μm or less, the photon 
throughput towards the detector significantly reduces while the detector 
noise remains constant, thus the signal to noise ratio (S/N) is strongly 
decreased. Moreover, when working with microbeams approaching in size 
the wavelength of mid-IR radiation (above 2.5 to 25 μm wavelength), the 
diffraction limit becomes dominant in the IR spectral interpretation. 
By exploiting Synchrotron Radiation (SR) as an IR source, the brightness 
of the photon flux density reaching the sample is no more a limitation in 
the illumination of microscopic sample features. High quality spectra of 
individual cells with a diameter around 15 µm, which is the average diameter 
of a granulocyte, were obtained at beamline B22. For reference, samples 
composed of very homogeneous cell populations were measured and usable 
spectra with acceptable S/R values were achieved with conventional source 
from larger areas (e.g. 50 μm), which demonstrated the complementarity of 
microFT-IR with conventional lab instruments.
The IR spectrum of a cell usually contains a large number of absorption 
bands, many of them can be confidently assigned to the molecular 
vibrations of a particular group, in particular analysing the ‘fingerprint 
region’. The unequivocal interpretation of pre-assigned vibrational mode 
is not straightforward because the common modes of different molecular 
components within a cell may overlap and the spectrum may reflect only 
the average biochemical composition. The development of the so-called 
molecular medicine requires the identification of biomarkers that can be 
associated to disease-specific molecular pathways. In an attempt to extend 
the biomedical applications of microFT-IR, we applied mid-IR analysis to 
search for specific vibrational components with the equivalent significance 
of a traditional cancer biomarker. That is: a specific gene, or a more or less 
expressed protein, or protein activity, or as some ‘…omics’ signatures. 
Specific protein components, for instance BCR/ABL oncoprotein, cannot be 
directly measured in the spectrum of leukemic cells without some labelling 
and/or other forms of pre-treatment in samples, and in the absence of a 
calibration method. Nevertheless, in perturbing cells, with drugs specifically 
targeting BCR/ABL-associated tyrosine kinase, we were able to identify 
some spectral components with the potential significance of IR biomarkers 
exhibiting the downstream effects of specific oncogene activity.
Cells interacting with their environment receive signals that are 
transduced to the nucleus through a complex array of biochemical signals 
known as signal transduction processes. These signaling events are specific 
for the agonist/s but can have some common features, like the activation 
of phosphorylation/dephosphorylation processes on a specific set of 
macromolecules. Biochemical, functional, structural and dynamical changes 
occurring also in complex systems subjected to specific perturbations can 
be identified by difference spectroscopy2. For instance, during typical time-
course or dose-response experiments with drugs, the spectral features from 
groups that do not change during the stimulation annihilated one another, 
and only the changes occurring as a consequence of the activation/inhibition 
become evident in the difference spectrum.
In the attempt to move microFTIR ‘from spectroscopy labs to Hospitals’, we 
have recently demonstrated with a set of experiments performed at the IR 
beamline B22 ‘MIRIAM’, that a specific region of mid-IR absorbance spectrum 
is associated to the reduction in tyrosine phosphorylation levels in human 
leukemic cell models following treatment with the tyrosine kinase inhibitor 
(TKI) imatinib-mesylate, the founder of a class of highly effective BCR/ABL 
inhibitors of clinical efficacy3. Moreover, we have also identified and cross-
validated some typical IR signatures of drug action in cells4 as shown in Fig. 1. 
To this scope we acquired SR-based microFT-IR spectra of individual 
leukemic cells exposed to the pro-apoptotic drug imatinib-mesylate (IMA). 
Typical IR signatures of cell apoptosis were identified by supervised data 
analysis in the spectra (Fig. 1 (A & B)). Unsupervised cluster analysis was 
applied to the dataset allowing the classification of the spectra of cells 
with apoptotic (drug-sensitive) and viable (drug-resistant) IR patterns (Fig. 
1 (C)). This application may suggest that a rapid and economic screening 
platform based on microFT-IR could be implemented for drug screening of 
compounds targeting phosphorylation processes or to monitor ex vivo in 
future, with minimal sample treatment, the efficacy of TKI treatment in the 
individual patient as hypothesised.  These qualitative measurements point to 
a possible application of the technique in clinical trial with patients, where 
the procedure could be used as a diagnostic tool influencing thereby the 
treatment of the patients. This could be a step forward for a more efficient 
and targeted personalised medicine.
Soft Condensed Matter Village   Beamline B22
3. Deininger, M. W. & Druker, B. J. Specific targeted therapy of chronic 
myelogenous leukemia with imatinib. Pharmacol Rev. 55, 401-423, 
(2003).
4. Bellisola, G. et al. Tracking infrared signatures of drugs in cancer cells 
by Fourier transform microspectroscopy. Analyst. 135, 3077-3086, 
(2010).
PMCID: PMC3236568 
Tools for cancer research and diagnosis: infrared spectroscopy 
and microscopy
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Since the middle of the 20th century, infrared (IR) spectroscopy coupled to microscopy has been used as a non destructive, label free, highly sensitive and specific analytical method to reveal molecular structure. Nowadays, synchrotron based IR microspectroscopy offers a signal-to-noise spectral quality unreachable by other broadband sources, and achieves 
the highest optically attainable IR spatial resolution on microscopic scale samples. This is particularly relevant in Life 
Sciences, with a significant progression of applications in biomedical research and in particular cancer studies. In view of 
the validation of the IR fingerprint region as a spectral marker of cancer and anticancer therapy follow up, we have recently 
performed a set of key experiments on leukemic blasts at the IR beamline B22 ‘MIRIAM’. The results on identification and 
cross-validation of IR markers of drug actions in the spectra of K562 leukemic blasts are in the following report. 
Figure 1: The identification and cross-validation of IR markers of drug actions in the spectra of K562 leukemic blasts. (A) The representative SR FT-IR absorbance spectra of viable (blue trace) and 
apoptotic (red trace) K562 blast cells exposed for 24 hours to 5 µM imatinib mesylate (IMA) in the interval of wavenumbers between 3800 and 850 cm-1. (B) The same base-line corrected spectra 
within the interval of wavenumbers 1800 and 850 cm-1 showing the significant shift of amide I and amide II towards (double-edged arrows) in the absorbance spectrum of the cell undergoing 
apoptosis (red line). (C)  The unsupervised recognition of the IR patterns of viable (drug-resistant) and apoptotic (drug-sensitive) K562 cells in samples, respectively. (D) The cumulative fractions 
of K562 blast cells with viable (blue) and apoptotic (red) IR patterns resulting from a typical dose-response experiment with IMA, respectively. (E) and (F) cross-validation of IR analysis by 
immunoblotting analysis of phosphorylated proteins. (E) cell lysated of untreated CTRL (lanes 1 and 2) and of K562 cells exposed to 5 µM IMA for 24 hours (lanes 3 and 4) were probed with anti-
phosphotyrosine antibodies PY99 and 4G10. (F) The cleaved 85 kDa band of poly(ADP-ribose) polymerase (PARP) is a molecular marker of cell apoptosis. (F) The relative percentages of dead cells 
determined by flow cytometric analysis in parallel untreated CTRL and IMA-treated K562 samples.  (E) and (F) were taken from ref. 4.
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